CellResearch Corporation Unveils Breakthrough PTT-6® for Stronger Hair and Scalp Health
News related to:CellResearch Corporation · 2 min read
SINGAPORE, Sept. 30, 2026 /CourierPR/ -- In a breakthrough, Singapore-based biotechnology pioneer CellResearch Corporation has unveiled new lab results proving its patented active complex, PTT-6®, significantly improves hair resilience and scalp health. The findings, reported on August 4 and September 8, 2026, provide rare, objective proof for two factors crucial to hair longevity: structural tensile strength and skin tolerance under harsh chemical stress.
At the Aesthetic and Anti-Aging Medicine World Congress (AMWC) Japan in Tokyo, presented jointly by Dr. Ivor Lim, consultant plastic surgeon and Group Chief Medical Officer at CellResearch Corporation, and Dr. Mikiko Hiraoka, board-certified dermatologist and founder of Tokyo's Ginza Richesse Clinic, the presentation highlighted the real-world clinical implications of PTT-6® in advanced scalp restoration.
The global hair and scalp care category is projected to climb from USD 93.6 billion in 2026 to USD 150.5 billion by 2033, marking a 7.0% compound annual growth rate (CAGR) and adding close to USD 57 billion within seven years. Hair loss and thinning products are the fastest-growing segment, forecast to compound at 8.6% a year to 2033.
PTT-6® has shown a 43% improvement in breaking work, a measure of the physical energy required to fracture a hair fiber. In laboratory testing, bleached human hair treated with PTT-6® demonstrated a 43% improvement in breaking work compared to untreated hair from the same batch. For salon professionals and colorists, this increase in structural resilience means hair can better withstand intensive chemical services, such as bleaching, perming, and thermal straightening, with significantly reduced risk of post-treatment snapping.
In a 28-day human study evaluating PTT-6® Scalp Activating Mist, once-daily application yielded a 14% measured reduction in scalp redness (p = 0.016), with 100% of participants confirming that the formula soothed irritation. Longer-term 12-week clinical evaluations demonstrated a 22% decrease in trans-epidermal water loss alongside a 45% increase in scalp moisture, effectively halving trichologist-assessed scalp sensitivity within one month.
At the cellular level, in vitro models showed that PTT-6® suppressed inflammatory signals (the cytokine TNF-alpha) by up to 30-fold, while increasing dermal papilla cell proliferation by 24%. By mitigating inflammatory cascades while simultaneously strengthening hair fiber resilience, PTT-6® offers salons and consumers a double benefit: protecting scalp health during advanced technical treatments while ensuring long-term hair quality and longevity.
Multi-center international data confirms PTT-6® directly drives visible hair regrowth and density. Across eight independent trials in six countries (including the USA, the UK, Singapore, Australia, Austria, and China), treatment evaluated in 238 patients yielded positive clinical responses in 225 cases: a 94% overall response rate. In a focused 12-week clinical study of 35 patients, quantitative photographic analysis demonstrated a 14% increase in total hair count and a 16% increase in average hair shaft thickness.
CellResearch Corporation is accelerating the international footprint of its professional cosmeceutical brand, CALECIM® Professional, targeting a global hair and scalp care market projected at USD 93.6 billion in 2026, where formulas addressing hair loss, thinning, and scalp health represent the fastest-growing sector.